Related Experiment Videos
Methotrexate therapy in systemic lupus erythematosus.
1Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil. emiliasato@reumato.epm.br
Lupus
|April 24, 2001
Summary
Methotrexate (MTX) shows promise for treating systemic lupus erythematosus (SLE) patients with skin or joint issues, especially when other treatments fail. While generally safe, careful monitoring for side effects is advised.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease.
- Limited controlled studies exist for methotrexate (MTX) in SLE treatment.
- Previous research primarily focused on cutaneous and articular manifestations.
Purpose of the Study:
- To review and synthesize evidence on methotrexate efficacy in SLE patients.
- To evaluate MTX effectiveness in various SLE manifestations, including lupus nephritis and pediatric cases.
- To assess MTX safety and tolerability in SLE management.
Main Methods:
- Systematic review of controlled and non-controlled studies involving MTX in SLE.
- Analysis of studies focusing on cutaneous, articular, and renal lupus.
- Inclusion of pediatric SLE cases and comparison of treatment outcomes.
Main Results:
- Majority of studies show good results for cutaneous and/or articular SLE.
- Conflicting results reported for lupus nephritis and pediatric SLE.
- Controlled trials indicate MTX effectiveness in antimalarial-resistant arthritis and mild SLE, allowing prednisone dose reduction.
- Adverse events were noted, but discontinuation due to toxicity was infrequent (around 10%).
Conclusions:
- Methotrexate, at low weekly doses, appears effective for SLE patients with articular/cutaneous involvement unresponsive to antimalarials and low-dose prednisone.
- MTX may benefit patients unable to reduce prednisone dosage due to persistent activity.
- Caution regarding potential side effects is necessary when using MTX for SLE.